A Novel Antimycobacterial Compound Acts as an Intracellular Iron Chelator

Efficient iron acquisition is crucial for the pathogenesis of Mycobacterium tuberculosis. Mycobacterial iron uptake and metabolism are therefore attractive targets for antitubercular drug development. Resistance mutations against a novel pyrazolopyrimidinone compound (PZP) that is active against M....

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Antimicrob Agents Chemother
Auteurs principaux: Dragset, Marte S., Poce, Giovanna, Alfonso, Salvatore, Padilla-Benavides, Teresita, Ioerger, Thomas R., Kaneko, Takushi, Sacchettini, James C., Biava, Mariangela, Parish, Tanya, Argüello, José M., Steigedal, Magnus, Rubin, Eric J.
Format: Artigo
Langue:Inglês
Publié: American Society for Microbiology 2015
Sujets:
Mechanisms of Action: Physiological Effects
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4356758/
https://ncbi.nlm.nih.gov/pubmed/25645825
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.05114-14
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires